Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 776 of 6351
-
AI reads routine heart tests to predict artery blockages
Diagnosis CompletedThe purpose of this study is to determine the efficacy, safety, and cost-effectiveness of AI-Gatekeeper software to assist clinicians in the diagnosis of coronary artery disease by predicting coronary artery stenosis (≥50%) from a multimodal AI technology that integrates clinical…
Sponsor: INFINITT Healthcare • Aim: Diagnosis
Last updated Sep 02, 2026 00:00 UTC
-
Can a smartphone app guide heart patients back to strength?
Disease control CompletedA two-parallel, evaluator-blind, single-center, randomized controlled trial was designed to assess the effectiveness of a home-based mobile guided exercise-based cardiac rehabilitation among patients undergoing Transcatheter Aortic Valve Replacement.
Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a 6,000-Person study unlock personalized depression care for asians?
Knowledge-focused OngoingSHAKTI (from the Sanskrit word for "power") is a 5-year natural history, longitudinal, prospective study of a cohort of 6,000 participants that will help uncover the socio-demographic, lifestyle, clinical, psychological, and neurobiological factors that contribute to antidepressa…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
Can a simple breathing trick outperform the standard heart maneuver?
Disease control CompletedThe goal of this clinical trial is to compare two physical techniques for treating paroxysmal supraventricular tachycardia in adults. This condition causes a fast, regular heartbeat that starts and stops suddenly. Participants must be medically stable and have the condition confi…
Sponsor: Salih Karakoyun • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug aims to stop liver scarring in Alpha-1 patients
Disease control Recruiting nowThe liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT b…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New daily pill aims to crush stubborn cholesterol in High-Risk patients
Disease control CompletedThe study is a placebo-controlled, double-blind, randomized, phase 3 study in participants with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors to evaluate the efficacy, safety and tolerability…
Phase 3 • Sponsor: NewAmsterdam Pharma • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New MRI-guided radiation aims to spare brain tissue in lung cancer patients
Disease control Recruiting nowThis study aims to explore the safety and efficacy of eliminating the planning target volume (PTV) margins based on MRI-guided adaptive stereotactic radiotherapy for non-small cell lung cancer (NSCLC) patients with brain metastasis.
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Radiation boosts immunotherapy in lung cancer trial
Disease control Recruiting nowThis is a randomized, controlled, open-label, multicenter phase II clinical trial comparing the efficacy and safety of low-dose radiation therapy and stereotactic body radiation therapy combined with PD-1 inhibitor (sintilimab) and standard platinum-based doublet chemotherapy ver…
Phase 2 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug shows promise for rare kidney disease
Disease control CompletedAnti-GBM disease is the most severe form of glomerulonephritis. Despite of the standard treatment including plasmapheresis and immunosuppressant, 70% of the patients still go into end-stage kidney disease. Complement has been shown to participate in the pathogenesis of anti-GBM d…
Phase 2 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Could your own bone marrow ease incurable chest pain?
Symptom relief Recruiting nowREGENERATE-COBRA will examine whether autologous stem cell treatment can improve angina symptoms and quality of life for patients with refractory angina. Patients will be randomised (randomly allocated with a 50:50 chance) to either the 'treatment' or the 'sham' group - they will…
Phase 2 • Sponsor: Barts & The London NHS Trust • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Could a chemo drug shrink prostate tumors in men with BRCA mutations?
Disease control Recruiting nowThis phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the…
Phase 2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for tough pancreatic cancer: combo therapy with or without radiation
Disease control Recruiting nowThis study is a single-arm, multi-center, multi-cohort, prospective clinical study initiated by the investigator. The indication of this study is: patients with advanced metastatic pancreatic cancer who have progressed after first-line chemotherapy. Eligible patients will be ass…
Phase 2 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Veterans with lung cancer may benefit from triple therapy approach
Disease control Recruiting nowThis study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
Phase 2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Antidepressant may ease pain and PTSD after trauma
Symptom relief Recruiting nowWith this prospective double-blinded, placebo controlled clinical trial we hypothesize that immediate (post-injury) intervention with Fluoxetine will prevent/mitigate the development of negative psychiatric symptomology such as PTSD and depression for victims of bodily trauma. We…
Phase 4 • Sponsor: University of Florida • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Can a Triple-Drug rechallenge tame colorectal cancer?
Disease control Recruiting nowThis is a non-profit phase II, open, clinical study of the combination of irinotecan plus cetuximab and envafolimab as a rechallenge regimen, in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients (according to liquid biopsy at baseline). Patients have been treat…
Phase 2 • Sponsor: Beijing Hospital • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
A simple spray before lung biopsy could curb dangerous bleeding
Disease control OngoingTransbronchial cryobiopsies are common procedures used to obtain tissue samples from airways for diagnostic purposes. While these procedures are safe, there is a risk of bleeding from the biopsy site. We are conducting a research study to assess the safety and effectiveness of us…
Phase 3 • Sponsor: Youssef Yammine • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug combo targets tough prostate cancer
Disease control Recruiting nowTo find the best dose of ADI-PEG20 that can be given in combination with carboplatin and cabazitaxel to patients with AVPC.
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New weekly shot challenges semaglutide for diabetes and weight loss
Disease control CompletedThis is a multicenter, randomized, Open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 6 mg OW versus Semalgutide 1 mg OW in obese(BMI≥28kg/m2) early T2D subjects. Subjects will be randomly assigned to IBI362 6 mg and Semalgutide 1 mg groups for 32 weeks…
Phase 3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Gene therapy trial targets rare heart disease in 10 patients
Disease control OngoingThis is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM
Phase 1/2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Smartphone app aims to combat malnutrition in head and neck cancer patients
Disease control Recruiting nowPatients with head and neck cancer requiring definitive or adjuvant radio(chemo)therapy can take part in the study. The aim is to record the nutritional status and diet of the patients during the trial and regularly at a period of 8 weeks after irradiation and to reduce the rate …
Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC